Belite Bio, Inc (BLTE) Q2 2026 Earnings Call Transcript

SA Transcripts 161.81K Followers Follow Belite Bio, Inc ( BLTE ) Q2 2026 Earnings Call August 13, 2026 4:30 PM EDT Company Participants Julie Fallon Yu-Hsin Lin - Chairman of the Board of Directors & CEO Hao-Yuan Chuang - CFO & Director Hendrik Scholl - Chief Medical Officer Nathan L. Mata - Chief Scientific Officer Conference Call Participants Judah Frommer - Morgan Stanley, Research Division Marc Goodman - Leerink Partners LLC, Research Division Tazeen Ahmad - BofA Securities, Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Yi Chen - H.C. Wainwright & Co, LLC, Research Division Presentation Operator Ladies and gentlemen, thank you for joining us, and welcome to the Belite Bio Second Quarter 2026 Earnings Call. [Operator Instructions]. I will now hand the conference over to Julie Fallon. Please go ahead. Julie Fallon Thank you for joining us. On the call today are Dr. Tom Lin, Chairman and CEO of Belite Bio; Dr. Hendrik Scholl, Chief Medical Officer; Dr. Nathan Mata, Chief Scientific Officer; and Hao-Yuan Chuang, Chief Financial Officer. Before we begin, let me point out that we will be making forward-looking statements that are based on our current expectations and beliefs. These statements are subject to certain risks and uncertainties, and actual results may differ materially. We encourage you to consult the risk factors discussed in our SEC filings for additional detail. Additionally, today, we will be discussing certain non-GAAP financial measures. Reconciliations to the most directly comparable GAAP measures are provided in the press release we issued today. And now I'll turn the call over to Dr. Lin. Dr. Lin? Yu-Hsin Lin Chairman of the Board of Directors & CEO Thank you, Julie. Good afternoon, everyone. Thank you for joining our second quarter 2026 Financial Results and Corporate Update Call. The first half of this year has been both exciting and deeply productive for Belite Bio. As we rapidly approach a